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ABSTRACT
The course, form and outcome of an acute 
respiratory illness, as well as its patho-histological 
features largely depend on the level of inflammatory 
cytokines. The most important proinflammatory 
cytokines and chemokines are: IL-1α, IL-1β, IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, IFN-γ, TNF-α and 
GM-CSF. There are many similarities in the human 
immune response to influenza, SARS and MERS-CoV. 
Available studies of COVID-19 show a completely 
different immune response, i.e. immunological 
indifference or suppression.
Influenza is a disease we have known for a long 
time. WHO has been successfully following the 
antigenic drift of influenza virus ever since 1952 
(WHO’s Global Influenza Surveillance and Response 
System (GISRS). This is necessary to monitor 
epidemiological characteristics of influenza as well 
as for the components of the seasonal vaccine 
which contains the antigenic characteristics of 
the subtypes and variants of influenza A virus that 
circulated in the previous season in the southern 
hemisphere. Throughout this period, many 
viruses and bacteria caused respiratory infections, 
sometimes in increasing epidemic numbers, but it 
was only the flu that caused serious problems. The 
epidemics were accompanied by high morbidity and 
significant mortality. Beta-corona viruses caused a 
serious warning in 2002 when SARS Cov-1 and MERS 
in 2012 appeared, followed by high mortality. Alpha 
corona viruses have been present all this time, but 
have caused mild upper respiratory infections and 
rhinitis, without serious consequences. Depending 
on the season and the region, corona viruses have 
been present in 10 to 35% of respiratory infections 
with the immune response to any infectious agent, 
may be mild, moderate and consequently heal, 
or severe when due to the high level of cytokines 
many barriers and membranes can be damaged 
and cause death. In influenza, the immune response 
is adequate. Only in a small percentage of cases, 
an overactive immune response is observed that 
causes damage and even death. SARS and MERS- 
CoV have been also shown to elicit a strong immune 
response. 
COVID-19 has been present for only a few months, 
and despite the efforts of many scientists, the 
epidemiological characteristics and pathogenesis of 
the disease are still not completely clear. Although 
COVID-19 belongs to beta corona viruses along 
with SARS and MERS-CoV, there are differences in 
the immune response. Whether COVID-19 weakens 
the immune system, or the immune system does 
not recognize it as a serious threat, there is a weak 
immune response during this infection. Such a 
significant discrepancy in the immune response 
can help   understand the pathogenesis of COVID 
19 and the causes of primary viral pneumonia and 
ARDS followed by high mortality.
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INTRODUCTION
The purpose of the present paper was to analyze 
the differences in the immune response between 
influenza, SARS and MERS-CoV on the one hand and 
COVID-19 - on the other, and to explain the possible 
causes of mortality in COVID-19. Papers from highly 
rated scientific journals, monographs and textbooks 
were reviewed to analyze the immune response to 
influenza during epidemics and pandemics, and 
to compare it to the immune response observed 
during corona infections.
Flu is caused by influenza types A and B, while 
influenza type C causes mild upper respiratory 
infections. Until now, pandemics have only been 
caused by influenza type A, with subtypes H1, H2 
and H3. During a flu epidemic, caused either by 
influenza virus type A or B, a clinical picture with 
severe symptoms of general infectious syndrome 
always develops. In infectious diseases, viral or 
bacterial, the symptoms of the general infectious 
syndrome appear due to the cytokine response. The 
severity of these symptoms, such as fever, malaise, 
headache, bone and muscle pain, drowsiness, sore 
throat, etc. depend on the levels of cytokines and 
other elements of the immune system that modulate 
the immune response. During influenza infection, 
there is secretion of the interferon-α (IFN-α), tumour 
necrosis factor-α (TNF-α), interleukin-1 (IL-1) α 
and β, interleukin-6 (IL-6), interleukin-8 (IL-8) and 
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monocyte-attracting chemokines (2, 7,12, 13, 14, 
15, 18, 22). A higher level of released cytokines 
has been accompanied by more pronounced 
symptoms of the general infectious syndrome. The 
human immune system senses the influenza virus 
as a serious threat and is activated immediately 
after the virus enters the respiratory epithelium 
cells. As a result of the rising    cytokine levels 
preceeding the death of the respiratory epithelium 
cells the clinical picture of flu is observed, whereby 
after an incubation of 1-2 days the symptoms of 
general infectious syndrome appear. Symptoms 
due to the death of a large number of   upper 
respiratory tract epithelial cells occur two to three 
days after the onset of the disease, such as sneezing, 
coughing, runny nose, and lacrimation. The latter 
are present for a long time after the symptoms of 
the general infectious syndrome have subsided. 
The temperature normalizes 4-5 days after the 
onset of the disease, as well as the other symptoms 
of the general infectious syndrome, as a result 
of the normalization of the    cytokine values and 
other elements of the inflamm a tory response of 
the humoral and cellular immunity. The symptoms 
caused by the death of the respiratory epithelium 
cells (sneezing, coughing, r u nny nose) remain 
present until those cells are restored (2, 14, 15, 16, 
22). But in a small number of people (0.01–0.02% of 
patients), the immune system  reacts too strongly, 
secreting very high doses of  cytokines, leading to 
a violent immune response th a t   damages   the 
barriers and membranes in th e  body. The most 
severe condition is encephal o pathy, which is 
associated with increased le v els of numerous 
cytokines, but in particular ,  with an increase in 
IL-6 levels. When   the blood concentration of IL-6 
is between 80 to 150 pg / ml  there is no risk of 
brain dysfunction. Above 150 pg / ml a mild brain 
dysfunction occurs. When the level of IL-6 exceeds 
6000 pg / mL,  the hematoenc e phalic barrier is 
damaged, and blood elements s uch as bilirubin, 
urea, and creatinine   that a re toxic to neurons 
come into contact with CNS cells. Due to the death 
of CNS cells, he clinical picture of encephalopathy 
develops. Encephalopathies a re severe conditions 
ending up in 30 to 50% mortality. Encephalopathies 
with IL6 values above 15 000 pg / mL always end in 
death. In addition, the impaired hematoencephalic 
barrier during influenza viral infection, is associated 
with significantly increase d  rates of purulent 
meningitis (7,16,19,20) .
Numerous studies have analyzed episodes of beta 
corona virus infections and the occurrence of 
SARS-CoV in 2002, and the 2012 Mers-CoV Middle 
East Respiratory Syndrome. (1, 6, 18, 25, 26, 27) 
In both cases,   a strong immune response and a 
cytokine storm with an increase in IL-8, IL-1β, IL-
1b and IL-6 were observed. IL-8 appears to be the 
major cytokine responsible for the inflammatory 
response in the lungs accompanied by infiltration of 
neutrophils, monocytes, and NK cells. Experiments 
in mice in which IFN- α, CCL2, IL-6, TNF- α, and IFN- 
γ had been induced, demonstrated inflammatory 
infiltrates with numerous neutrophils, monocytes, 
and NK cells.  IL-1β was associated with tissue 
damage, neutrophil infiltration, acute inflammatory 
reactions, and severe respiratory viral infection.
From the numerous papers on COVID-19 available 
until now, it is evident that there is no strong immune 
response to this infection (Table 1). Leukopenia 
or normal leukocyte counts are present in most of 
the cases. The frequently observed lymphopenia is 
somewhat surprising. Procalcitonin level is normal. 
CRP increase is detected in a small percentage of 
cases. (1, 3, 4, 5, 12, 17,18, 22-24, 26, 27). Chuan 
Chin (9) analyzed the immune characteristics in a 
group with 452 patients with COVID-19, of which 
286 were with severe infection, and 168 - with a 
mild clinical form. There was a slight increase in IL-6 
values   only to 13.3 pg / ml in patients with a mild 
clinical picture, as opposed to 25.2 pg / ml in severe 
cases (n o rmal values   0.0–7.0 pg / mL). The other 
tested cytokines, IL -2R, IL-8, IL-10, and TNF-α as well 
as serum IgM, IgG, and IgA were within the normal 
ranges    in both groups.  The absolute numbers of 
helper   (CD3 + CD4 +) and suppressor T cells (CD3 
+ CD8 +) in patients with COVID-19 were below the 
normal values. The decrease of helper T cells in the 
group with severe infection was more pronounced. 
The function of CD4+, CD8+ T cells, and NK cells (in 
terms of  IFN-γ express ion) were in normal ranges 
and no s i g nificant diff erence was established 
between severe and non-severe cases. Lymphocyte 
subsets were analyzed in 44 patients with COVID-19 
on admission. The total number of lymphocytes: B 
cells, T cells, and NK cells was significantly lower in 
patients with COVID-19 (mean values  of 852.9 cells/
μL, and even lower) in severe cases, (743.6 vs. 1020) 
in the non-severe group. Similar results were also 
obtained by Yishan (22) who analyzed 125 patients, 
103 of whom had COVID-19 and 22 non-COVID-19 
pneumonia. Wei-jie Guan’s analysis of 1,099 patients 
concluded that there was a difference in the clinical 
picture and immune response between COVID-19 
and othe r  acute respi ratory infectio n s (influenza, 
SARS CoV - 1 , MERS Cov (19). Other aut h ors (4, 6, 
18, 26) a l so found th at the values   of interleukins 
and othe r  cytokines i n COVID-19 were  either 
unchange d  or slightly  elevated. Leuk o penia and 
lymphope n i a were pres ent. The fact t h at there 
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is no strong immune response during COVID-19 
upper respiratory tract infection is in favour of the 
mild clinical picture whereby the symptoms of the 
general infectious syndrome are either absent or 
of low intensity. By the second week of April, more 
than 2,350,000 SARS-CoV-2 positive patients have 
been registered worldwide, over 162,000 of whom 
have died. So far, not a single case of COVID-19 who 
has  died from encephalopathy has been described. 
This fact is also in favour of the absence of strong 
immune response, or cytokine storm in SARS-CoV-2 
infection.
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Cytokine storm is the term for a dramatic increase 
in cytokine concentrations. Cytokine storm occurs 
at concentrations greater than 4.000 pg/ml for NF-
α, IFN-γ, IL 1, and IL 8,   greater than 3.000 pg/ml for 
IL2 and IL 6, more than 2.000 pg/ml for IL 4, more 
than 1.500 pg/ml for IL 10 and more than 400 pg/
ml for IL-12 (9, 10)
Based on previous experience with respiratory 
infections, the absence of   strong immune response 
may be due to several reasons. The first possible 
option is that the respective causal agent is part of 
the normal microflora of the upper respiratory tract 
and the immune system does not recognize it as a 
foreign antigen and a danger to the body. The second 
option is the existence of specific secretory IgA. After 
an acute respiratory infection, in addition to IgM and 
IgG antibodies, the level of IgA secretory antibodies 
increases. These virus-specific IgA antibodies, in the 
case of COVID-19, neutralize the virus before it enters 
the cells of the respiratory epithelium, preventing 
the infection, so that viral antigens do not come into 
contact with the human immune system at all. It is 
possible that we currently have a second wave of 
COVID-19. IgG antibodies to COVID-19 are found in 
about ten percent of the population. A third option 
is the existence of cross-immunity so that antibodies 
to alpha corona viruses (causing seasonal infections 
in humans) neutralize SARS CoV-2 as well. The fourth 
possible explanation for the lack of a strong reaction 
(and absence of general infectious syndrome) is the 
nature of the virus itself, which manages to avoid the 
initial strong immune response, , as is the case with HIV 
infection for example. The virus itself does not cause 
much damage when   entering the body, so there is 
no proper immune response. HIV enters the body 
without much resistance, after which it multiplies in 
the cells of the immune system (CD4 T lymphocytes). 
Indeed, in the case of SARS-CoV-2, it is paradoxical to 
reach a state of leukopenia lymphopenia, a decrease 
in T lymphocytes, for a short period of several days, 
in an acute infection with short incubation of about 
4 (2 -14) days).
Regarding the occurrence of primary viral pneumonia, 
there is a large difference in the clinical manifestations 
of epidemic vs. pandemic influenza. During epidemics 
lower respiratory infections and primary influenza 
pneumonia are not typically observed. In general, 
pneumonia during influenza epidemics is due to 
a secondary bacterial infection. Outbreaks in inter-
pandemic period are caused by   small drifts in the 
antigenic structure of viral   hemagglutinin. When 
the new variant appears, memory B lymphocytes 
recognize a similar antigen, followed by a rapid rise in 
antibody titters from the corresponding clone. At the 
same time, there is a complete immune response to the 
new antigenic influenza virus variant. But partial cross-
action is enough to slow the spread of the influenza 
virus to the lower respiratory tract. When a large 
antigenic shift occurs and a new subtype of influenza 
A virus appears in the circulation, there is a lack of 
cross-immunity help, permitting the new subtype to 
descend in the lower respiratory system and cause 
primary viral pneumonia. In addition, during the first 
encounter with the new subtype of influenza A virus, 
a significant number of people have a very strong 
immune response and secretion of large amounts of 
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cytokines. These primary influenza pneumonias are 
the cause of high mortality during pandemics. (16, 
19, 20) Unlike pandemic influenza viruses, COVID-19 
in a large percentage of patients (about 20%) causes 
primary viral pneumonia. It is also very unusual that 
a pathogen that is not extremely virulent (has not yet 
been shown to have a direct cytopathogenic effect) 
is able to cause massive bilateral pneumonia. The 
second paradox is that patients with uncompromised 
immune system have no problem recovering from 
this massive viral pneumonia. (4, 5, 8, 27) This is 
contrary to previous experience in science, where 
primary viral pneumonias are accompanied by high 
mortality. On the average, COVID-19 pneumonia 
occurs 18 days after the infection, when the virus is 
no longer present in the body. in contrast to primary 
viral pneumonia   presenting during the acute phase 
of pandemic influenza There is a rich finding on X-rays, 
but no enlarged lymph nodes in the mediastinum 
(4.8). Although there is evidence of pneumonia,   very 
few inflammatory cells are detected in the autopsy. All 
this data require consideration and analysis of another 
possible condition or co-infection in the settings of 
COVID-19.
Conclusions
The host’s immune response to influenza virus is 
strong, sometimes even excessive.
The host’s immune response during SARS and MERS 
is strong.
Although it is a similar upper respiratory infection, 
the immune response in COVID-19 is weak, and in 
some patients it is even suppressed.
Although SARS-CoV-2 does not stimulate the 
immune response, it does manage to cause primary 
viral pneumonia in 20% of those infected.
Patients with well-functioning immune system   are 
(paradoxically) easily cured from massive bilateral 
COVID-19 pneumonia.
Co-infection with another infectious agent or 
other condition might be the cause of COVID-19 
pneumonia.
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